Patoulias and colleagues have made a relevant commentary entitled “Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors in patients with heart failure with reduced ejection fraction” [1] on our meta-analysis [2] recently published in the European Journal of Internal Medicine (EJIM). In that commentary, the authors, by implementing a further meta-analysis, assessed whether chronic kidney disease (CKD) status and type 2 diabetes (T2D) status affected the efficacy of sodium-glucose transporter 2 (SGLT2) inhibitors in patients with heart failure and reduced ejection fraction (HFrEF).
